FDA Reform, But what About The Tea Tasters?

1 October 1995

The US Senate has voted to end the Board of Tea Experts, which has been sipping imported tea since 1897 to make sure it tastes right. No similar panel exists for coffee or other foods.

Two years ago the Senate thought it had eliminated the board when Congress voted to forbid any money for it, say Associated Press reports. But the board survived. In separate legislation, Congress voted to raise the fee paid by industry for tea-monitoring. The industry also began paying the $50 annual fee, travel costs and daily expenses for each of the board's six outside experts when they meet in Brooklyn to sample tea for two days.

Democratic Senator Harry Reid says that taxpayers are still paying the $68,600 salary of Robert Dick, the Food and Drug Administration chemist who has run the board for 56 years, and those of the FDA staffers who support the program, and the room used for tasting, or about two-thirds of the program's $200,000 annual cost.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight